Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study
Annals of Hematology · 21.11.2026
DOI: 10.1007/s00277-026-07359-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.11.2026. Verfasst von Xuewu Zhang und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zhang, X., Yao, Q., Zhang, X., Zhou, X., Xu, G., You, L., Yang, M., Qian, J., Meng, H., Yu, W., Jin, J., & Tong, H. (2026). Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07359-5
Vancouver
Zhang X, Yao Q, Zhang X, Zhou X, Xu G, You L, et al. Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study. Annals of Hematology. 2026. doi:10.1007/s00277-026-07359-5
BibTeX
@article{Zhang2026,
author = {Zhang, Xuewu and Yao, Qiumei and Zhang, Xiang and Zhou, Xinping and Xu, Gaixiang and You, Liangshun and Yang, Min and Qian, Jiejing and Meng, Haitao and Yu, Wenjuan and Jin, Jie and Tong, Hongyan},
title = {Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07359-5}
}
EUVIMED